BackFidelity Select Biotechnology Portfolio Overview
Fidelity Select Biotechnology Portfolio

Fidelity Select Biotechnology Portfolio Return on Equity

Latest ROE for Fidelity Select Biotechnology Portfolio: -0.77% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

-0.77%

Return on Equity

-0.77%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Fidelity Select Biotechnology Portfolio (FBIOX) FAQ

Fidelity Select Biotechnology Portfolio posts a ROE of -0.77%. That is above the sector sector average of -4.11%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For its sector stocks, a ROE near -4.11% is typical. Fidelity Select Biotechnology Portfolio's -0.77% is higher that level. That is roughly 81.3% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Fidelity Select Biotechnology Portfolio's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -0.77%; use YoY and peer views to separate noise from signal.

Context for FBIOX's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -4.11%), and (3) consistency with growth and profitability. This page covers the first two; Fidelity Select Biotechnology Portfolio's other metric pages and overview cover the third.